Shaperon to Present Atopic Dermatitis and Alopecia Areata Therapeutic Results at Leading Global Conference in the US

Invited as Keynote Speaker at the Inflammasome Therapeutics Summit
World-Class Professional Conference in Inflammasome Research
Accelerating Global Collaboration and Commercialization Expected

On October 27, Shaperon announced that CEO Sung Seungyong has been invited as a keynote speaker at the 7th Inflammasome Therapeutics Summit, which will be held in Boston, USA, from November 4 to 6. He will present the clinical and preclinical research results of the company's GPCR19-targeted inflammasome modulator.

This invitation demonstrates the high level of interest from the global pharmaceutical industry in GPCR19-based inflammasome control technology and its clinical achievements, and is expected to further accelerate global collaboration and commercialization going forward.

At this summit, CEO Sung will discuss the latest research trends and development directions for inflammasome therapeutics together with Allen Watt, CEO of NodThera; Brian Levy, CEO of InflamX Therapeutics; Kiran Bhaskar, Ph.D. of Theravectys Biologics; and Rashmin Savani, Ph.D. of Azome Therapeutics.

The Inflammasome Therapeutics Summit is considered the world's leading professional conference in the field of inflammasome research, which is emerging as a next-generation target for the treatment of inflammatory diseases. Major global pharmaceutical companies such as Novartis, Pfizer, NodThera, and Zyversa participate to share research outcomes and commercialization strategies. Each year, the summit is known for active discussions on technology partnerships, licensing deals, and various forms of collaboration.

Inflammasome inhibitors are regarded as a key next-generation anti-inflammatory therapeutic strategy in the global pharmaceutical market. However, existing NLRP3 inhibitors have been limited by only regulating the activation stage of the inflammatory response, failing to achieve the expected clinical efficacy.

Pharmaceutical companies are actively pursuing technology transfers and mergers and acquisitions (M&A) to discover new regulatory targets that constitute inflammasomes. For example, Genentech acquired the Irish biotech company Inflazome for approximately 700 billion KRW (about 700 million USD). Leading companies such as Novartis and Novo Nordisk are also actively working to secure related technologies.

Amid these industry trends, Shaperon's GPCR19 agonist has drawn attention by showing positive results in the phase 2b part 1 clinical trial for atopic dermatitis. 'NuGel,' the world's first GPCR19-targeted inflammasome inhibitor, has demonstrated differentiated efficacy compared to existing therapies and has been selected as the keynote topic for this conference. In addition to the clinical results for atopic dermatitis, Shaperon will also present preclinical data on various inflammatory skin diseases, including acne, rosacea, and diabetic foot ulcers.

As of last year, the global market size was approximately 20 billion USD for atopic dermatitis, 13 billion USD for acne, 2.5 billion USD for rosacea, 1.1 billion USD for diabetic foot ulcers, and 3.3 billion USD for alopecia areata. This presentation is expected to attract significant attention from the market and investors.

In CEO Sung's keynote speech, the potential of Shaperon's candidate substances as next-generation alternative therapies to overcome the side effects of steroidal anti-inflammatory drugs will be highlighted. His original immunological theory, "Molecular debris triggers inflammation," published in Nature Reviews Immunology, is once again drawing attention.

Based on approximately 20 years of research experience in inflammasome inhibitors, Shaperon has established a next-generation drug development platform utilizing artificial intelligence (AI). This platform is a multivariate system that predicts not only target suitability but also absorption, metabolism, distribution, toxicity, and synthetic feasibility of drugs, and is recognized as an innovative technology that reduces drug development risks and increases the probability of success.

The GPCR19 agonist 'Nualeratine,' developed through the AI platform, demonstrated efficacy in suppressing inflammasome activation and increasing regulatory T cells to improve autoimmune alopecia. In preclinical studies, 'Nualeratine' showed a 74% higher hair regrowth rate compared to competing drugs, proving its superior efficacy.

A Shaperon representative stated, "This global conference keynote speech is an official opportunity to present our clinical and preclinical data, as well as our AI drug development technology, on the world stage," adding, "We expect this to further accelerate the global technology transfer and commercialization of our key drug candidates."